Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

[Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012].

Stegmann B, Rexroth CA, Wenzel-Seifert K, Haen E.

Z Kinder Jugendpsychiatr Psychother. 2015 Mar;43(2):101-14. German.

PMID:
25951625
2.

Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study.

Wenzel-Seifert K, Brandl R, Hiemke C, Haen E.

Pharmacopsychiatry. 2014 Nov;47(7):239-44. doi: 10.1055/s-0034-1390477. Epub 2014 Nov 5.

PMID:
25372890
3.

Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.

Sigurdsson HP, Hefner G, Ben-Omar N, Köstlbacher A, Wenzel-Seifert K, Hiemke C, Haen E.

J Neural Transm (Vienna). 2015 May;122(5):721-9. doi: 10.1007/s00702-014-1317-9. Epub 2014 Sep 26.

PMID:
25257248
4.

[Can serotonin syndrome also be caused by tramadol administration alone?].

Wenzel-Seifert K, Haen E.

Med Monatsschr Pharm. 2013 Sep;36(9):346-7. German. No abstract available.

PMID:
24069648
5.

[Depressive disorders in childhood and adolescence - an analysis of KinderAGATE 2010].

Stegmann B, Wenzel-Seifert K, Haen E.

Z Kinder Jugendpsychiatr Psychother. 2013 Mar;41(2):109-19. doi: 10.1024/1422-4917/a000218. German.

PMID:
23425613
6.

QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Wenzel-Seifert K, Wittmann M, Haen E.

Dtsch Arztebl Int. 2011 Oct;108(41):687-93. doi: 10.3238/arztebl.2011.0687. Epub 2011 Oct 14. Review.

7.

[Antidepressants, antipsychotics and metabolic risks].

Wittmann M, Hübner-Liebermann B, Wenzel-Seifert K, Hausner H.

MMW Fortschr Med. 2011 Mar 3;153(9):42-4. German. No abstract available.

PMID:
21638864
8.

Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors.

Wenzel-Seifert K, Wittmann M, Haen E.

Pharmacopsychiatry. 2010 Nov;43(7):279-81. doi: 10.1055/s-0030-1263167. Epub 2010 Oct 6. No abstract available.

PMID:
20927699
9.
10.

The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors.

Seifert R, Wenzel-Seifert K.

Life Sci. 2003 Sep 19;73(18):2263-80. Review.

PMID:
12941430
11.

Functional differences between human formyl peptide receptor isoforms 26, 98, and G6.

Wenzel-Seifert K, Seifert R.

Naunyn Schmiedebergs Arch Pharmacol. 2003 May;367(5):509-15. Epub 2003 Apr 5.

PMID:
12679864
12.

Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor.

Seifert R, Wenzel-Seifert K, Burckstummer T, Pertz HH, Schunack W, Dove S, Buschauer A, Elz S.

J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. Epub 2003 Mar 6.

PMID:
12626648
13.

Critical role of N-terminal N-glycosylation for proper folding of the human formyl peptide receptor.

Wenzel-Seifert K, Seifert R.

Biochem Biophys Res Commun. 2003 Feb 14;301(3):693-8.

PMID:
12565836
14.

GDP affinity and order state of the catalytic site are critical for function of xanthine nucleotide-selective Galphas proteins.

Gille A, Wenzel-Seifert K, Doughty MB, Seifert R.

J Biol Chem. 2003 Mar 7;278(10):7822-8. Epub 2002 Dec 23.

15.

Efficient adenylyl cyclase activation by a beta2-adrenoceptor-G(i)alpha2 fusion protein.

Seifert R, Wenzel-Seifert K, Arthur JM, Jose PO, Kobilka BK.

Biochem Biophys Res Commun. 2002 Nov 15;298(5):824-8.

PMID:
12419329
16.

Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.

Seifert R, Wenzel-Seifert K.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Nov;366(5):381-416. Epub 2002 Sep 6. Review.

PMID:
12382069
17.

Similarities and differences in the coupling of human beta1- and beta2-adrenoceptors to Gs(alpha) splice variants.

Wenzel-Seifert K, Liu HY, Seifert R.

Biochem Pharmacol. 2002 Jul 1;64(1):9-20.

PMID:
12106601
19.

Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type agonists.

Kelley MT, Bürckstümmer T, Wenzel-Seifert K, Dove S, Buschauer A, Seifert R.

Mol Pharmacol. 2001 Dec;60(6):1210-25.

PMID:
11723228
20.

Similar apparent constitutive activity of human histamine H(2)-receptor fused to long and short splice variants of G(salpha).

Wenzel-Seifert K, Kelley MT, Buschauer A, Seifert R.

J Pharmacol Exp Ther. 2001 Dec;299(3):1013-20.

PMID:
11714890
21.
22.

Defective Gi protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodontitis.

Seifert R, Wenzel-Seifert K.

J Biol Chem. 2001 Nov 9;276(45):42043-9. Epub 2001 Sep 14.

23.
24.

Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.

Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK.

J Pharmacol Exp Ther. 2001 Jun;297(3):1218-26.

PMID:
11356949
25.

Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins.

Wenzel-Seifert K, Seifert R.

Mol Pharmacol. 2000 Nov;58(5):954-66.

PMID:
11040042
26.

Quantitative analysis of formyl peptide receptor coupling to g(i)alpha(1), g(i)alpha(2), and g(i)alpha(3).

Wenzel-Seifert K, Arthur JM, Liu HY, Seifert R.

J Biol Chem. 1999 Nov 19;274(47):33259-66.

27.

GPCR-Galpha fusion proteins: molecular analysis of receptor-G-protein coupling.

Seifert R, Wenzel-Seifert K, Kobilka BK.

Trends Pharmacol Sci. 1999 Sep;20(9):383-9.

PMID:
10462762
28.
29.

Examining the efficiency of receptor/G-protein coupling with a cleavable beta2-adrenoceptor-gsalpha fusion protein.

Seifert R, Wenzel-Seifert K, Gether U, Lam VT, Kobilka BK.

Eur J Biochem. 1999 Mar;260(3):661-6.

30.
31.

High constitutive activity of the human formyl peptide receptor.

Wenzel-Seifert K, Hurt CM, Seifert R.

J Biol Chem. 1998 Sep 11;273(37):24181-9.

34.
35.
36.
38.

G-protein-coupled receptors in HL-60 human leukemia cells.

Klinker JF, Wenzel-Seifert K, Seifert R.

Gen Pharmacol. 1996 Jan;27(1):33-54. Review.

PMID:
8742493
39.

Mastoparan may activate GTP hydrolysis by Gi-proteins in HL-60 membranes indirectly through interaction with nucleoside diphosphate kinase.

Klinker JF, Hagelüken A, Grünbaum L, Heilmann I, Nürnberg B, Harhammer R, Offermanns S, Schwaner I, Ervens J, Wenzel-Seifert K, et al.

Biochem J. 1994 Dec 1;304 ( Pt 2):377-83.

40.

Evidence that inhibition of phorbol ester-induced superoxide anion formation by cyclosporin A in phagocytes is not mediated by direct inhibition of protein kinase C.

Wenzel-Seifert K, Schächtele C, Hummel R, Grünbaum L, Seifert R.

Biochem Pharmacol. 1994 Aug 30;48(5):859-64.

PMID:
8093097
41.

N-protein kinase C isoenzymes may be involved in the regulation of various neutrophil functions.

Wenzel-Seifert K, Schächtele C, Seifert R.

Biochem Biophys Res Commun. 1994 May 16;200(3):1536-43.

PMID:
8185608
42.

Oleic acid inhibition of Na+/D-glucose transport in isolated renal brush-border membranes: role of lipid physical parameters and trans Na(+)-inhibition.

Wagner S, Wenzel-Seifert K, Volbracht L, Sorgenfrei D, Ebel H.

Biochim Biophys Acta. 1994 Mar 23;1190(2):309-18.

PMID:
8142431
43.

Lipopeptides activate Gi-proteins in dibutyryl cyclic AMP-differentiated HL-60 cells.

Klinker JF, Höer A, Schwaner I, Offermanns S, Wenzel-Seifert K, Seifert R.

Biochem J. 1993 Nov 15;296 ( Pt 1):245-51.

44.

Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Wenzel-Seifert K, Seifert R.

Naunyn Schmiedebergs Arch Pharmacol. 1993 Jul;348(1):7-13.

PMID:
7690907
46.
48.

Fulminant calcinosis in two patients after kidney transplantation.

Wenzel-Seifert K, Harwig S, Keller F.

Am J Nephrol. 1991;11(6):497-500.

PMID:
1819217
49.

Nucleotide-, chemotactic peptide- and phorbol ester-induced exocytosis in HL-60 leukemic cells.

Wenzel-Seifert K, Seifert R.

Immunobiology. 1990 Nov;181(4-5):298-316.

PMID:
1966023
50.

Repeated dialysis anaphylaxia.

Wenzel-Seifert K, Sharma AM, Keller F.

Nephrol Dial Transplant. 1990;5(9):821-4.

PMID:
2129358

Supplemental Content

Loading ...
Support Center